Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

Home Clinical Trial Sponsors and OrganizationsTAKEDA DEVELOPMENT CENTRE EUROPE LTD.

TAKEDA DEVELOPMENT CENTRE EUROPE LTD.

ACTIVE

1 Kingdom Street, London, United Kingdomwww.takeda.co.ukSubsidiary

Also known as:

takeda global research and development

Part of Takeda Pharmaceutical Co., Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

193

191 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

151

78.2%

Phase 4

2

1.0%

Trial Status Distribution

Active, not recruiting

191

99.0%

Completed

2

1.0%

Clinical Trials

Trials sponsored by this organization (193)

Program to allow continuation of treatment with Entyvio (Vedolizumab IV) for patients with ulcerative colitis and Chron¿s disease who previously participated in a clinical trial with this same treatment

Active, not recruiting

Jun 2021331 participants

Vedolizumab IV 300 mg in the Treatment of Chronic Pouchitis

Active, not recruiting

Jun 2021102 participants

Effectiveness and Safety of Vedolizumab SC as Maintenance Therapy in Ulcerative Colitis.

Active, not recruiting

Jun 2021383 participants

Efficacy and Safety of Vedolizumab IV in Subjects With Ulcerative Colitiscompared to Adalimumab SC

Active, not recruiting

Jun 2021771 participants

Effectiveness and Safety of Vedolizumab SC as Maintenance Therapy in Crohn's Disease

Active, not recruiting

Feb 2021644 participants

ong-term effectiveness and Safety of Vedolizumab SC as a Therapy for Ulcerative Colitis and Crohn's Disease

Active, not recruiting

Jan 2021692 participants

Vedolizumab IV in subjects with Crohn's Disease

Active, not recruiting

Jan 2021101 participants

Efficacy and Safety of Vedolizumab IV in the treatment of Primary Sclerosing Cholangitis in patients with Inflammatory Bowel Disease

Active, not recruiting

Jan 202199,999 participants

Page 1 of 25

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials193
Approvals
News

Back to Organizations